Last C$0.13 CAD
Change Today 0.00 / 0.00%
Volume 157.2K
SBM On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 3:59 PM 11/20/14 All times are local (Market data is delayed by at least 15 minutes).

sirona biochem corp (SBM) Snapshot

Open
C$0.13
Previous Close
C$0.13
Day High
C$0.13
Day Low
C$0.13
52 Week High
08/6/14 - C$0.20
52 Week Low
07/18/14 - C$0.09
Market Cap
16.6M
Average Volume 10 Days
231.5K
EPS TTM
C$-0.03
Shares Outstanding
127.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SIRONA BIOCHEM CORP (SBM)

Related News

No related news articles were found.

sirona biochem corp (SBM) Related Businessweek News

No Related Businessweek News Found

sirona biochem corp (SBM) Details

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada. The company develops programs in three areas, including diabetes and cancer therapeutics; anti-aging and depigmenting agent in cosmeceuticals; biological ingredients, such as inducers and adjuvants for biological development. It develops a sodium glucose co-transporter inhibitor for the treatment of Type 2 diabetes; and a cancer vaccine antigen. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Founded in 2006

sirona biochem corp (SBM) Top Compensated Officers

Founder, Chairman of the Board, Interim Chief...
Total Annual Compensation: C$95.0K
Chief Financial Officer and Director
Total Annual Compensation: C$102.0K
Compensation as of Fiscal Year 2013.

sirona biochem corp (SBM) Key Developments

Sirona Biochem Names Attila Hajdu as Chief Business Development Officer

Sirona Biochem Corp. announced that it has named Mr. Attila Hajdu as Chief Business Development Officer. Prior to joining Sirona Biochem, Attila held various senior leadership positions within GlaxoSmithKline and Astellas Pharma, accumulating 17 years of experience in Sales, Marketing, R&D Finance, Medical Affairs and Business Development.

Sirona Biochem Corp. Launches Anti-Aging Preclinical Studies

Sirona Biochem Corp. announced that it has launched the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem's subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys. Biogalenys has been chosen to work with the team of scientists at TFChem to develop the studies on the anti-aging technology. The research will provide preclinical data supporting multiple targeted applications using novel in vitro tests with varying stress conditions and cell types. The purpose is to both validate the compounds, and to satisfy the standard cohort of cosmetic safety studies. The data will then be used to determine the optimal commercial applications and joint venture partners.

Sirona Biochem Announces Positive Results of PK Study for Type 2 Diabetes

Sirona Biochem Corp. announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes. The pharmacokinetic (PK) study of SBM-TFC-039 confirms an excellent oral bioavailability of SBM-TFC-039. Bioavailability refers to the drug's ability to be absorbed into the body. The results are in accordance with results of an earlier study conducted by Sirona Biochem. The drug was administered as a single dose in SD rats. The first milestone of the license agreement with Wanbang Biopharmaceuticals is expected after the next scheduled study, assessing toxicology in rats during a 14 day test. This will trigger a second payment to Sirona from Wanbang Biopharmaceuticals as part of the $9.5 million in upfront and milestone payments.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBM:CN C$0.13 CAD 0.00

SBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBM.
View Industry Companies
 

Industry Analysis

SBM

Industry Average

Valuation SBM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 56.1x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 55.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIRONA BIOCHEM CORP, please visit www.sironabiochem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.